Australia
· Delayed Price · Currency is AUD Imugene Statistics
Total Valuation
Imugene has a market cap or net worth of AUD 304.93 million. The enterprise value is 213.10 million.
| Market Cap | 304.93M |
| Enterprise Value | 213.10M |
Important Dates
The next estimated earnings date is Wednesday, February 26, 2025.
| Earnings Date | Feb 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Imugene has 7.44 billion shares outstanding. The number of shares has increased by 12.96% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 7.44B |
| Shares Change (YoY) | +12.96% |
| Shares Change (QoQ) | +6.01% |
| Owned by Insiders (%) | 11.78% |
| Owned by Institutions (%) | 11.04% |
| Float | 6.25B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 58.49 |
| PB Ratio | 2.54 |
| P/TBV Ratio | 3.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.42 |
| EV / Sales | 42.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.96 |
Financial Position
The company has a current ratio of 3.86, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.86 |
| Quick Ratio | 3.61 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -296.48 |
Financial Efficiency
Return on equity (ROE) is -97.23% and return on invested capital (ROIC) is -57.24%.
| Return on Equity (ROE) | -97.23% |
| Return on Assets (ROA) | -50.87% |
| Return on Capital (ROIC) | -57.24% |
| Revenue Per Employee | 994,006 |
| Profits Per Employee | -29.94M |
| Employee Count | 5 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.95% in the last 52 weeks. The beta is 3.39, so Imugene's price volatility has been higher than the market average.
| Beta (5Y) | 3.39 |
| 52-Week Price Change | -60.95% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 52.39 |
| Average Volume (20 Days) | 18,558,317 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imugene had revenue of AUD 4.97 million and -149.68 million in losses. Loss per share was -0.02.
| Revenue | 4.97M |
| Gross Profit | 4.97M |
| Operating Income | -141.82M |
| Pretax Income | -149.68M |
| Net Income | -149.68M |
| EBITDA | -137.45M |
| EBIT | -141.82M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 93.11 million in cash and 1.28 million in debt, giving a net cash position of 91.83 million or 0.01 per share.
| Cash & Cash Equivalents | 93.11M |
| Total Debt | 1.28M |
| Net Cash | 91.83M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 118.25M |
| Book Value Per Share | 0.02 |
| Working Capital | 83.74M |
Cash Flow
In the last 12 months, operating cash flow was -101.73 million and capital expenditures -7.07 million, giving a free cash flow of -108.80 million.
| Operating Cash Flow | -101.73M |
| Capital Expenditures | -7.07M |
| Free Cash Flow | -108.80M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -2,853.55% |
| Pretax Margin | -3,011.66% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Imugene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.96% |
| Shareholder Yield | -12.96% |
| Earnings Yield | -51.50% |
| FCF Yield | -35.68% |
Stock Splits
The last stock split was on November 12, 2002. It was a reverse split with a ratio of 0.13333.
| Last Split Date | Nov 12, 2002 |
| Split Type | Reverse |
| Split Ratio | 0.13333 |
Scores
Imugene has an Altman Z-Score of 5.76.
| Altman Z-Score | 5.76 |
| Piotroski F-Score | n/a |